Proteios is developing an innovative approach that empowers an organization’s discovery and manufacturing of Advanced Therapy Medicinal Products (ATMPs). Some of the anticipated advantages of ATMPs include: highly personalized therapy, direct application through infusion, longer lasting effect, address complex diseases, and improving health-related quality of life. Complex manufacturing and compliance with GMP standards has been a major challenge for the progress of ATMPs. The Proteios Chimera Platform is enabling: 1) new discoveries in Preclinical Research to better understand disease at the molecular level, 2) the cost-effective manufacturing of Biopharmaceuticals, Cell Therapies, Gene Therapies, and Antibody Therapeutics, 3) and the development of novel molecular diagnostics.